Shock cardiogénico

cardiogenic shock (cs) is a severe clinical and hemodynamic condition, but treatable and with reasonable chance of recovery. traditional literature has focused on its high mortality. while it continues to be true, there is growing evidence that early revascularization allows patients to have greater survival and an acceptable quality of life. in the past two decades, the treatment of myocardial infarction has experienced steady progress. a better understanding of the pathophysiology of acute coronary syndromes, the introduction of new drugs and new strategies for myocardial revascularization have allowed a progressive reduction in mortality from stroke in patients who are admitted to a hospital prepared for evaluation , diagnosis and treatment. however, the incidence of cs post infarction has remained stable, with values ranging between 5 and 15% and is the leading cause of hospital death in patients with acute myocardial infarction (ami). although the cs is in the form early in the context of an ami, it is not diagnosed quickly enough and hemodynamic compromise is usually underestimated. the early revascularization yields benefits at any level of risk and is a key aim in the treatment of this severe and not so uncommon clinical condition.